TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces the following September 2024 investor events:
Investor Conference Presentations
• Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on
Wednesday, September 4, 2024
• 2024 Wells Fargo Healthcare Conference at 12:45 p.m. ET on Thursday,
September 5, 2024
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
Oncology Webcast Information
• European Society for Medical Oncology (ESMO) 2024 conference call and webcast at 14:30 CEST/8:30 AM EDT on Monday, September 16, 2024
Regeneron will host a conference call and simultaneous webcast to share updates on the company’s oncology portfolio. A link to the webcast may be accessed from the ‘Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com/events-and-presentations. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$738.00 |
| Daily Change: | -6.50 -0.87 |
| Daily Volume: | 1,015,957 |
| Market Cap: | US$80.010B |
November 15, 2024 November 13, 2024 November 06, 2024 October 31, 2024 October 24, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
